Mathieu Boudreau Email & Phone Number

Taipei, Tw

Taipei, Tw

As Chief Business Officer and member of the Foresee executive team, I play a leading role in architecting, implementing and executing Foresee’s corporate vision and strategy, seeking to sculpt an optimal path forward, utilizing creative approaches to growth, value creation and problem solving, always in concert with key stakeholders and in an environment of trust and camaraderie.

Taipei, Tw

As Vice President of Business Development and member of the Foresee executive team, I play a leading role in architecting, implementing and executing Foresee’s corporate business development/licensing strategy, with a focus on fostering partnerships and collaborations, leveraging Foresee’s product pipeline, namely its transformative early stage clinical and preclinical first-in-class programs targeting immune-fibrotic and mitochondrial-mediated lung diseases, cardiometabolic diseases and several rare diseases. As well as its NDA/EMA submission stage prostate cancer drug.

Belleville, On, Ca

As head of Corporate Development & Licensing, part of the new leadership team, I played a leading role in shaping Telesta, implementing and executing corporate development strategy, with a focus on bringing to the market (through US commercial infrastructure and through partnerships) its lead MCNA Phase 3 bladder cancer product, for which a BLA was submitted to the U.S. FDA, accepted for filing by the FDA and designated for Priority Review with a PDUFA date of February 27, 2016. While at Telesa I led several strategic transactions, including a significant license agreement for its Phase 3 uro-oncology program with global specialty pharmaceutical company, Ipsen.

Montreal, Quebec, Ca

Responsible for the business strategy and executing the business development plan for the Discovery Research and Innovative Drug Development Group within Scientific Affairs. This includes responsibility for out-licensing, in-licensing, exploring and implementing innovative R&D financing and partnership models related to the early stage drug candidate portfolio emerging from the discovery research group.

Montreal, Québec, Ca

Part of the business development team responsible for the identification/sourcing, preliminary evaluation and negotiation of late stage/commercial product in-licensing/acquisition opportunities in the areas of Urology, Oncology, Gastroenterology and Acute Care/Hospital.

Ca

Aegera Therapeutics Inc. was acquired by Pharmascience Inc. in May 2011. Aegera was focused on the discovery of first-in-class/best-in-class small molecule therapeutics targeting innate immune, co-stimulatory and apoptotic signaling in oncology, immunology and neurology, with programs from discovery through Phase 2. Several significant partnerships/licenses were established over the years.

Ph.D., Neuroscience

B.Sc., Biochemistry